Net Income (Loss) Attributable to Parent in USD of ELITE PHARMACEUTICALS INC /NV/ from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $13,702,407.000.
  • ELITE PHARMACEUTICALS INC /NV/ Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $13,923,489.000.
  • ELITE PHARMACEUTICALS INC /NV/ annual Net Income (Loss) Attributable to Parent for 2024 was -$4,314,659.000, a 121% decline from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Net Income (Loss) Attributable to Parent for 2023 was $20,108,631.000, a 465% increase from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Net Income (Loss) Attributable to Parent for 2022 was $3,561,846.000, a 60% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $13,923,489 $13,702,407 +$24,738,636 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$10,815,147 -$5,884,715 -$6,500,488 -10.6% 01 Apr 2025 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 -$4,314,659 $16,997,737 +$13,671,870 +4.1% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 -$17,986,529 -$10,891,940 -$11,598,294 -16.4% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 -$6,388,235 -$11,036,229 -$25,970,830 -1.7% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 $19,582,595 $615,773 -$526,036 -46.1% 01 Apr 2024 30 Jun 2024 10-Q 14 Nov 2025
Q1 2024 $20,108,631 $3,325,867 +$4,555,121 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $15,553,510 $706,354 -$2,263,724 -76.2% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025
Q3 2023 $17,817,234 $14,934,601 +$13,419,462 +8.9% 01 Jul 2023 30 Sep 2023 10-Q 13 Feb 2025
Q2 2023 $4,397,772 $1,141,809 +$835,926 +2.7% 01 Apr 2023 30 Jun 2023 10-Q 13 Feb 2025
Q1 2023 $3,561,846 -$1,229,254 -$3,657,991 -1.5% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $7,219,837 $2,970,078 +$686,665 +30.1% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 $6,533,172 $1,515,139 -$281,838 -15.7% 01 Jul 2022 30 Sep 2022 10-Q 14 Feb 2024
Q2 2022 $6,815,010 $305,883 -$2,083,235 -87.2% 01 Apr 2022 30 Jun 2022 10-Q 14 Feb 2024
Q1 2022 $8,898,245 $2,428,737 +$2,911,360 01 Jan 2022 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $5,986,885 $2,283,413 +$271,280 +13.5% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023
Q3 2021 $5,715,605 $1,796,977 -$684,585 -27.6% 01 Jul 2021 30 Sep 2021 10-Q 14 Feb 2023
Q2 2021 $6,400,190 $2,389,118 +$1,311,769 +1.2% 01 Apr 2021 30 Jun 2021 10-Q 14 Feb 2023
Q1 2021 $5,088,421 -$482,623 -$1,418,991 -1.5% 01 Jan 2021 31 Mar 2021 10-K 29 Jun 2022
Q4 2020 $6,507,412 $2,012,133 +$3,872,813 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022
Q3 2020 $2,634,599 $2,481,562 +$4,077,303 01 Jul 2020 30 Sep 2020 10-Q 14 Feb 2022
Q2 2020 -$1,442,704 $1,077,349 +$797,647 +2.9% 01 Apr 2020 30 Jun 2020 10-Q 14 Feb 2022
Q1 2020 -$2,240,351 $936,368 +$3,600,073 01 Jan 2020 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 -$5,840,424 -$1,860,680 +$483,638 +20.6% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021
Q3 2019 -$6,324,062 -$1,595,741 +$987,791 +38.2% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020
Q2 2019 -$7,311,853 $279,702 +$1,967,468 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 -$9,279,321 -$2,663,705 +$165,295 +5.8% 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020
Q4 2018 -$9,444,616 -$2,344,318 -$1,854,318 -3.8% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020
Q3 2018 -$7,590,298 -$2,583,532 -$4,398,532 -2.4% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$3,191,766 -$1,687,766 +$480,994 +22.2% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 -$3,672,760 -$2,829,000 +$357,000 +11.2% 01 Jan 2018 31 Mar 2018 10-K 14 Jun 2018
Q4 2017 -$4,029,760 -$490,000 -$2,157,000 -1.3% 01 Oct 2017 31 Dec 2017 10-K 14 Jun 2018
Q3 2017 -$1,872,760 $1,815,000 -$2,423,000 -57.2% 01 Jul 2017 30 Sep 2017 10-K 14 Jun 2018
Q2 2017 $550,240 -$2,168,760 -$3,267,760 -3% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 $3,818,000 -$3,186,000 -$11,685,000 -1.4% 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018
Q4 2016 $15,503,000 $1,667,000 +$13,900,000 01 Oct 2016 31 Dec 2016 10-K 14 Jun 2018
Q3 2016 $1,603,000 $4,238,000 +$5,919,000 01 Jul 2016 30 Sep 2016 10-K 14 Jun 2018
Q2 2016 -$4,316,000 $1,099,000 -$3,633,000 -76.8% 01 Apr 2016 30 Jun 2016 10-K 14 Jun 2018
Q1 2016 -$683,000 $8,499,000 +$14,849,000 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018
Q4 2015 -$15,532,000 -$12,233,000 -$19,650,000 -2.6% 01 Oct 2015 31 Dec 2015 10-K 14 Jun 2018
Q3 2015 $4,118,000 -$1,681,000 -$7,929,000 -1.3% 01 Jul 2015 30 Sep 2015 10-K 14 Jun 2018
Q2 2015 $12,047,000 $4,732,000 +$6,826,000 01 Apr 2015 30 Jun 2015 10-K 14 Jun 2018
Q1 2015 $5,221,000 -$6,350,000 +$80,448,000 +92.7% 01 Jan 2015 31 Mar 2015 10-K 14 Jun 2017
Q4 2014 -$75,227,000 $7,417,000 +$8,479,000 01 Oct 2014 31 Dec 2014 10-K 14 Jun 2017
Q3 2014 -$83,706,000 $6,248,000 +$15,886,000 01 Jul 2014 30 Sep 2014 10-K 14 Jun 2017
Q2 2014 -$99,592,000 -$2,094,000 -$3,016,000 -3.3% 01 Apr 2014 30 Jun 2014 10-K 14 Jun 2017
Q1 2014 -$96,576,000 -$86,798,000 -$88,394,948 -55.4% 01 Jan 2014 31 Mar 2014 10-K 15 Jun 2016
Q4 2013 -$8,181,052 -$1,062,000 -$10,425,166 -1.1% 01 Oct 2013 31 Dec 2013 10-K 15 Jun 2016
Q3 2013 $2,244,114 -$9,638,000 -$10,687,909 -10.2% 01 Jul 2013 30 Sep 2013 10-K 15 Jun 2016
Q2 2013 $12,932,023 $922,000 +$11,444,095 01 Apr 2013 30 Jun 2013 10-K 15 Jun 2016
Q1 2013 $1,487,928 $1,596,948 +$8,602,112 01 Jan 2013 31 Mar 2013 10-K 30 Jun 2014
Q4 2012 -$7,114,184 $9,363,166 +$602,171 +6.9% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014
Q3 2012 -$7,716,355 $1,049,909 -$12,869,412 -92.5% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013
Q2 2012 $5,153,057 -$10,522,095 +$20,211,331 +65.8% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 -$15,058,274 -$7,005,164 +$9,600,037 +57.8% 01 Jan 2012 31 Mar 2012 10-K 21 Jun 2013
Q4 2011 -$24,658,311 $8,760,995 +$2,832,783 +47.8% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013
Q3 2011 -$27,491,094 $13,919,321 +$12,055,097 +6.5% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 -$39,546,191 -$30,733,426 -$25,964,032 -5.4% 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012
Q1 2011 -$13,582,159 -$16,605,201 01 Jan 2011 31 Mar 2011 10-K 29 Jun 2012
Q4 2010 $5,928,212 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012
Q3 2010 $1,864,224 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011
Q2 2010 -$4,769,394 01 Apr 2010 30 Jun 2010 10-Q/A 19 Aug 2011

ELITE PHARMACEUTICALS INC /NV/ Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$4,314,659 -$24,423,290 -1.2% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 $20,108,631 +$16,546,785 +4.6% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 $3,561,846 -$5,336,399 -60% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024
2021 $8,898,245 +$3,809,824 +74.9% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023
2020 $5,088,421 +$7,328,772 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022
2019 -$2,240,351 +$7,038,970 +75.9% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021
2018 -$9,279,321 -$5,606,149 -1.5% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020
2017 -$3,673,172 -$7,484,353 -2% 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019
2016 $3,811,181 +$4,494,193 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018
2015 -$683,012 -$5,903,617 -1.1% 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018
2014 $5,220,605 +$46,481,502 01 Apr 2014 31 Mar 2015 10-K 14 Jun 2017
2013 -$41,260,897 -$42,748,825 -28.7% 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016
2012 $1,487,928 +$16,546,202 01 Apr 2012 31 Mar 2013 10-K 30 Jun 2014
2011 -$15,058,274 -$1,476,115 -10.9% 01 Apr 2011 31 Mar 2012 10-K 21 Jun 2013
2010 -$13,582,159 01 Apr 2010 31 Mar 2011 10-K 29 Jun 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.